

References

I-291

1. Mintun MA, Lo AC, Evans CD, et al. Donanemab in early alzheimer's disease. *NEJM*. 2021; 384(18):1691-1704.
2. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic alzheimer's disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*. 2023; 330(6):512-527.
3. Kisunla (donanemab-azbt), injection for intravenous use [package insert]. Eli Lilly, Inc. Indianapolis, IN. Revised 07/2024.
4. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Donanemab-azbt.
5. Micromedex DrugDex Compendium®. 2024. Donanemab-azbt.